Investors

DateTitle 
May 25, 2017Lisa Conte, CEO of Jaguar Animal Health and Napo Pharmaceuticals, to Present at the Southern California Investment Forum May 31, 2017 in Los AngelesPrinter Friendly Version
May 24, 2017Napo Pharmaceuticals’ New Mytesi Video Calls Attention to the Continuing Widespread Problem of Diarrhea in People Living With HIV/AIDSPrinter Friendly Version
May 10, 2017Jaguar Animal Health and Napo Pharmaceuticals Appoint Dr. Pravin Chaturvedi to Chair Scientific Advisory BoardPrinter Friendly Version
Apr 28, 2017Jaguar Signs Distribution Agreement for Japan for Neonorm Foal & Neonorm CalfPrinter Friendly Version
Apr 06, 2017Jaguar and Napo Issue Commercial UpdatesPrinter Friendly Version
Mar 31, 2017Jaguar Animal Health and Napo Pharmaceuticals Enter Definitive Merger AgreementPrinter Friendly Version
Mar 28, 2017Jaguar Enters Exclusive Evaluation Period With Multinational Animal Health Pharmaceutical Firm Regarding Equilevia, Jaguar’s Drug Product Candidate for Equine Gastric Ulcer SyndromePrinter Friendly Version
Mar 14, 2017Jaguar Animal Health Seeks MUMS Designation for Canalevia for Exercise-Induced Diarrhea in DogsPrinter Friendly Version
Mar 03, 2017Jaguar Animal Health to Participate in 29th Annual ROTH Conference the Week of March 13th in Orange County, CaliforniaPrinter Friendly Version
Feb 28, 2017Napo Pharmaceuticals Signs Agreement with Alamo Pharma Services to Launch National Sales Force for MytesiPrinter Friendly Version
Feb 14, 2017Study Supporting Herd-wide Reduction in Incidence and Severity of Diarrhea With Prophylactic Use of Neonorm Calf Published in Journal of Dairy SciencePrinter Friendly Version
Feb 08, 2017Jaguar Animal Health Enters Binding Agreement of Terms to Merge with Napo PharmaceuticalsPrinter Friendly Version
Feb 02, 2017Jaguar Animal Health Begins Entry Into Organic Market With Neonorm CalfPrinter Friendly Version
Jan 31, 2017Jaguar Animal Health, Elanco Enter Global Collaboration for Development, Co-Promotion of CanaleviaPrinter Friendly Version
Jan 05, 2017Jaguar Animal Health to Participate in Biotech Showcase 2017 Week of January 9th in San FranciscoPrinter Friendly Version
Dec 19, 2016Jaguar Animal Health Appoints Dr. Ari Azhir to Board of DirectorsPrinter Friendly Version
Dec 12, 2016Jaguar Animal Health and Henry Schein, Inc. Sign Exclusive Distribution Agreement for Neonorm FoalPrinter Friendly Version
Dec 09, 2016Jaguar Animal Health Exhibits Neonorm Foal at American Association of Equine Practitioners Annual ConventionPrinter Friendly Version
Nov 23, 2016Jaguar Animal Health Announces Private Placement of Common Stock and WarrantsPrinter Friendly Version
Nov 14, 2016Jaguar Animal Health Issues Racing Data Summary for Horses Participating in the Company’s Recently Completed Dose Determination Study for its Drug Product Candidate for Equine Gastric Ulcer SyndromePrinter Friendly Version
Oct 18, 2016Jaguar Animal Health Announces Final Topline Results for Proof-of-Concept Study for Secretory Diarrhea in DogsPrinter Friendly Version
Oct 06, 2016Jaguar Animal Health and Napo Pharmaceuticals Announce Details for Proposed MergerPrinter Friendly Version
Sep 07, 2016Jaguar Animal Health Signs Exclusive Distribution Agreement for Croton lechleri Botanical Extract for Pigs and Dairy Cattle in the Chinese MarketplacePrinter Friendly Version
Sep 01, 2016Jaguar Animal Health Announces Additional Topline Results from Study of Second-Generation Formulation of Neonorm Calf Conducted in Association with Cornell University College of Veterinary MedicinePrinter Friendly Version
Jul 25, 2016Jaguar Animal Health Announces Positive Preliminary Topline Results of Two Chinese-sponsored Farm Studies to Evaluate the Safety and Effectiveness of Neonorm Botanical Extract in PigletsPrinter Friendly Version
Jun 30, 2016Jaguar Animal Health Appoints Leading Oncologist and Drug Development Executive as Chief Scientific OfficerPrinter Friendly Version
Jun 17, 2016Jaguar Animal Health Announces Positive Topline Results of University Study of Second-Generation Formulation of Neonorm Calf and Commercialization Strategy UpdatesPrinter Friendly Version
Jun 09, 2016Jaguar Animal Health Announces $15 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLCPrinter Friendly Version
May 04, 2016Jaguar Animal Health Initiates Dose Determination Study with the Target Commercial Paste Formulation of SB-300, the Company’s Drug Product Candidate for Treatment of Equine Gastric Ulcer SyndromePrinter Friendly Version
Apr 19, 2016SB-300, Jaguar’s Drug Product Candidate for the Treatment of Gastric Ulcers, Enables Continued Therapy in Performance Horses in Accordance with Standard Testing GuidelinesPrinter Friendly Version
Apr 13, 2016Jaguar Animal Health Obtains Protocol Concurrence From FDA for Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in DogsPrinter Friendly Version
Apr 06, 2016Jaguar Animal Health Appoints John Micek III to Board of DirectorsPrinter Friendly Version
Feb 22, 2016Jaguar Animal Health Appoints Dr. Philippe Brianceau as Chief Veterinary OfficerPrinter Friendly Version
Feb 16, 2016Jaguar’s SB-300 Drug Product Candidate in DevelopmentPrinter Friendly Version
Feb 09, 2016Jaguar Animal Health, Inc. Announces Closing of Public Offering; Secures Funding Through Anticipated Launch of First Prescription Drug Product CandidatePrinter Friendly Version
Feb 03, 2016Jaguar Animal Health, Inc. Prices 2,000,000 Common Share OfferingPrinter Friendly Version
Jan 28, 2016Jaguar Animal Health Reports Topline Findings for its Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in HorsesPrinter Friendly Version
Jan 07, 2016Jaguar Animal Health Initiates University Study to Further Investigate Possible Prophylactic and Prebiotic Benefits of a Second-Generation Formulation of Neonorm in Dairy CalvesPrinter Friendly Version
Dec 22, 2015Jaguar Animal Health Initiates Pivotal Field Study to Evaluate Safety and Effectiveness of Canalevia Drug Product Candidate for Treatment of Acute Diarrhea in DogsPrinter Friendly Version
Dec 21, 2015Jaguar Animal Health Announces Positive Results in University Pilot Safety Study of Crofelemer in HorsesPrinter Friendly Version
Dec 18, 2015Jaguar Animal Health Announces Positive Results of Investigator-Initiated Follow-up Neonorm Study in FoalsPrinter Friendly Version
Dec 16, 2015Jaguar Animal Health Appoints Karen Wright as Chief Financial OfficerPrinter Friendly Version
Dec 15, 2015Jaguar Animal Health Completes Enrollment for Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in HorsesPrinter Friendly Version
Dec 03, 2015Jaguar Animal Health Initiates University Pilot Safety Study to Evaluate Use of Crofelemer for the Treatment of Diarrhea Associated with Acute Colitis in HorsesPrinter Friendly Version
Nov 23, 2015Jaguar Animal Health to Present at the 2015 LD Micro Conference on December 3rd in Los AngelesPrinter Friendly Version
Nov 16, 2015Jaguar Animal Health Announces Positive Results from Proof-of-Concept Study of Neonorm in FoalsPrinter Friendly Version
Nov 05, 2015Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate the Safety and Effectiveness of an Investigational New Animal Drug Candidate for the Treatment of Gastrointestinal Ulcers in HorsesPrinter Friendly Version
Oct 27, 2015University Study Supports Benefit of Jaguar Animal Health’s Neonorm Calf on Intestinal Microbiome in Pre-weaned Dairy CalvesPrinter Friendly Version
Oct 26, 2015U.S. Patent and Trademark Office Issues Notices of Allowance in Two Pending NP-500 Patent Applications Licensed Exclusively by Jaguar Animal Health for Veterinary UsePrinter Friendly Version
Oct 26, 2015Jaguar Animal Health to Host Analyst and Investor Day on November 16, 2015 in New York CityPrinter Friendly Version
Oct 15, 2015Jaguar Animal Health Signs Crofelemer Formulation Development and Manufacturing Contract with PatheonPrinter Friendly Version
Oct 07, 2015Jaguar Animal Health Completes Second Neonorm Field Study Indicating Beneficial Effect of Product on Pre-Wean Weight Gain & Normalization of Stool Formation in Dairy Calves Beyond Current Standard of CarePrinter Friendly Version
Oct 02, 2015Jaguar Animal Health to Present at the Aegis Capital 2015 Growth ConferencePrinter Friendly Version
Sep 28, 2015Jaguar Animal Health Signs Crofelemer Manufacturing & Supply Agreement with Glenmark Pharmaceuticals Ltd.Printer Friendly Version
Sep 25, 2015Jaguar Animal Health Initiates Proof-of-Concept Study to Evaluate Safety, Tolerability & Efficacy of Neonorm in FoalsPrinter Friendly Version
Sep 02, 2015Study Evaluating Effect of Jaguar Animal Health’s Neonorm on Diarrhea in Newborn Dairy Calves Published in Journal of Dairy SciencePrinter Friendly Version
Aug 25, 2015Jaguar Animal Health to Attend the 2015 KC Animal Health Investment ForumPrinter Friendly Version
Aug 19, 2015Jaguar Animal Health Secures Debt FinancingPrinter Friendly Version
Aug 19, 2015Jaguar Animal Health Submits All Required Major Technical Sections of New Animal Drug Application for CanaleviaPrinter Friendly Version
Jul 16, 2015KCSA Strategic Communications to Lead Investor Relations Program for Jaguar Animal HealthPrinter Friendly Version
Jul 07, 2015Jaguar Animal Health Appoints Dr. Victoria Lewis as Chief of Clinical DevelopmentPrinter Friendly Version
Jul 01, 2015Jaguar Completes Study in Dogs with Chemotherapy-Induced Diarrhea with Commercial Formulation of CanaleviaPrinter Friendly Version
Jun 30, 2015Jaguar Animal Health, Inc. Added to Russell Microcap IndexPrinter Friendly Version
Jun 09, 2015Jaguar Animal Health Field Study Confirms Beneficial Effect of Neonorm on Average Daily Weight in CalvesPrinter Friendly Version
Jun 03, 2015Jaguar Animal Health Appoints Industry Expert Folkert Kamphuis to Board of DirectorsPrinter Friendly Version
May 13, 2015Jaguar Animal Health, Inc. Announces Pricing of Initial Public OfferingPrinter Friendly Version
Mar 04, 2015Jaguar Animal Health Files Two Provisional Patent Applications, Deepening its Pipeline of Proprietary Gastrointestinal Products for AnimalsPrinter Friendly Version
Feb 26, 2015Jaguar Animal Health Signs Agreement with Latin America’s Largest Veterinary Biotechnology CompanyPrinter Friendly Version
Feb 19, 2015Jaguar Animal Health Announces Outcome of Canine Proof-of-Concept Study for CanaleviaPrinter Friendly Version
Feb 10, 2015Jaguar Animal Health Files Ninth Investigational New Animal Drug ApplicationPrinter Friendly Version
Feb 05, 2015Jaguar Animal Health Signs Distribution Agreement with Vedco and Kicks off National Neonorm Calf Marketing CampaignPrinter Friendly Version
Dec 22, 2014Jaguar Animal Health Initiates Filing of Its First New Animal Drug Application with FDAPrinter Friendly Version
Dec 04, 2014Jaguar Animal Health Completes Equine Study for Safety & Palatability of Neonorm™ Foal Gastrointestinal ProductPrinter Friendly Version
Nov 21, 2014Jaguar Animal Health Appoints Former Merial Executive to Head Regulatory AffairsPrinter Friendly Version
Sep 29, 2014Jaguar Animal Health, Inc. Launches First Product, Neonorm™ Calf, at World Dairy ExpoPrinter Friendly Version
Sep 17, 2014Jaguar Animal Health, Inc. Files Eighth Investigational New Animal Drug ApplicationPrinter Friendly Version
Jul 08, 2014Jaguar Animal Health Names VP, Commercial OperationsPrinter Friendly Version
Mar 03, 2014Jaguar Files INADAs for Diarrhea in Companion Animals and HorsesPrinter Friendly Version
Feb 05, 2014Jaguar Announces Initial Close of Series A RoundPrinter Friendly Version
Jan 14, 2014Drug Application For Chemo-induced Diarrhea In Dogs Moving ForwardPrinter Friendly Version
Print Page Print Page | E-mail Page Email Page | RSS Feeds RSS Feeds | E-mail Alerts Email Alerts | Financial Tear Sheet Financial Tear Sheet